earnings-product-pipeline — скилл для Claude Code: анализ пайплайна
Скилл earnings-product-pipeline извлекает данные о разработке продуктов из отчётов о прибылях компаний: статусы клинических испытаний, регуляторные заявки, сроки вывода на рынок.
MIT 265 установок ★ 132 обновлён 2026-06-05
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-codeЧто делает earnings-product-pipeline
Скилл разбирает транскрипты earnings calls и собирает информацию о пайплайне продуктов. Ищет упоминания фаз испытаний (Phase 1, Phase 2, Phase 3), заявок в регуляторы (IND, NDA, BLA), дат вывода продукта и инвестиций в R&D. Возвращает структурированную таблицу с ключевыми вехами, сроками, статусами trial'ов и ссылками на страницы транскрипта.
Требует настроенный Octagon MCP — без него запросы не выполняются. Поддерживает фильтрацию по типу данных: можно запросить только regulatory updates или только launch timelines. Генерирует follow-up вопросы для углублённого анализа и строит catalyst calendar с оценкой рисков по каждому событию.
Примеры запросов: Extract product development and pipeline updates from MRNA's latest earnings call discussion, What regulatory submissions or approvals were discussed in PFE's call?, Extract clinical trial updates from JNJ's earnings transcript.
Какие задачи решает
- извлечь данные о клинических испытаниях из earnings call
- собрать timeline регуляторных заявок компании
- отследить прогресс пайплайна продуктов по транскриптам
- построить календарь catalyst'ов с датами Phase 3 data
- найти R&D приоритеты в отчёте о прибылях
Примеры запросов агенту
- Извлеки обновления пайплайна продуктов из последнего earnings call
MRNA - Какие регуляторные заявки обсуждались в earnings call
PFE? - Собери информацию о клинических испытаниях из earnings transcript
JNJ
Как установить earnings-product-pipeline
1Через Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code2Вручную: положить файлы
~/.claude/skills/earnings-product-pipeline/SKILL.mdПапка скилла целиком; для одного проекта — .claude/skills/earnings-product-pipeline/
1Через Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a codex2Вручную: положить файлы
.agents/skills/earnings-product-pipeline/SKILL.mdДля всех проектов — ~/.agents/skills/
1Через Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a cursor2Вручную: положить файлы
.cursor/skills/earnings-product-pipeline/SKILL.mdCursor читает и .agents/skills/, и .claude/skills/
1GitHub CLI
gh skill install OctagonAI/skills skills/earnings-product-pipeline2Вручную: положить файлы
.github/skills/earnings-product-pipeline/SKILL.md1Через Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a gemini-cli2Командой платформы
gemini skills install https://github.com/OctagonAI/skills --path skills/earnings-product-pipelineВручную: положить файлы
.devin/skills/earnings-product-pipeline/SKILL.mdСтарый путь .windsurf/skills/ тоже читается
Через Skills CLI (Vercel)
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a opencodeClaude.ai
Упакуйте папку в zip и загрузите в Settings → Capabilities → Skills
По шагам, с командами для каждой платформы: Как установить скилл в Claude Code: пять способов
Вопросы об earnings-product-pipeline
Как установить earnings-product-pipeline в Claude Code?
Выполни npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code, затем открой ~/.claude/skills/earnings-product-pipeline/SKILL.md.
Что делает earnings-product-pipeline?
Извлекает из earnings calls данные о разработке продуктов: статусы испытаний, regulatory submissions, launch timelines. Возвращает структурированную таблицу с датами и ссылками на страницы транскрипта.
Что нужно для работы earnings-product-pipeline?
Настроенный Octagon MCP. Без него скилл не может выполнять запросы к earnings calls.
Исходный текст
SKILL.md · MIT
--- name: earnings-product-pipeline description: Extract product development and pipeline updates from earnings calls, including clinical trial progress, regulatory submissions, and launch timelines. --- # Earnings Product Pipeline Extract product development and pipeline updates from earnings call transcripts, including R&D milestones, clinical trial progress, regulatory submissions, and product launch timelines. ## Prerequisites Ensure Octagon MCP is configured. See [references/mcp-setup.md](references/mcp-setup.md) for installation instructions. ## Workflow ### Step 1: Extract Pipeline Updates Use the Octagon MCP to analyze product pipeline discussions: ``` Extract product development and pipeline updates from <TICKER>'s latest earnings call discussion. ``` ### Step 2: Targeted Pipeline Analysis Focus on specific aspects of product development: ``` # Full Pipeline What product pipeline updates were discussed in <TICKER>'s earnings call? # Clinical Trials Extract clinical trial updates from <TICKER>'s earnings transcript. # Regulatory Progress What regulatory submissions or approvals were discussed in <TICKER>'s call? # Launch Timeline Extract product launch timelines from <TICKER>'s earnings call. # R&D Investments What R&D priorities were highlighted in <TICKER>'s earnings transcript? # Stage Progression Which products advanced to new stages in <TICKER>'s pipeline? ``` ## Expected Output The skill returns structured pipeline analysis including: | Component | Description | |-----------|-------------| | Development Milestones | Key progress updates | | Clinical Trials | Trial status and data timelines | | Regulatory Submissions | FDA/EMA filings and approvals | | Launch Timeline | Expected commercialization dates | | Portfolio Overview | Stage-by-stage breakdown | | Follow-up Questions | AI-generated questions for deeper research | | Source Citations | Transcript page references | ## Example Query ``` Extract product development and pipeline updates from MRNA's latest earnings call discussion. ``` ## Example Response **Moderna, Inc. (MRNA) Product Development and Pipeline Updates (Q4 2024)** Moderna highlighted key product development and pipeline updates in their earnings call: **Product Development Milestones** - **Methylmalonic Acidemia (MMA) Test Products**: Achieving critical milestones with three regulatory submissions filed - **CMV Vaccine**: Anticipating final Phase 3 results in 2025 - **Flu and Norovirus Vaccines**: Both in Phase 3 trials, with data timelines contingent on case accrual - **INT Adjuvant Melanoma**: Progress dependent on patient accrual - **PA (Pneumonia) Vaccine**: Awaiting data from a registrational study, with plans to initiate a new MMA registrational study within the year **Portfolio Overview** - Approved Products: 2 - Advanced-Stage Candidates: 3 - Phase 3/Pivotal Studies: 6 ongoing The updates underscore Moderna's expanding mRNA platform pipeline. **Follow-up Questions** - What are the specific regulatory submissions for MMA test products? - What are the enrollment targets for the flu and norovirus Phase 3 trials? - What are the primary endpoints for the INT adjuvant melanoma study? **Source**: MRNA_Q42024, Page: 4 ## Pipeline Stage Framework ### Development Stages | Stage | Description | Probability of Success | |-------|-------------|------------------------| | Discovery | Early research | 5-10% | | Preclinical | Lab/animal studies | 10-15% | | Phase 1 | Safety, dosing | 15-25% | | Phase 2 | Efficacy signal | 25-40% | | Phase 3 | Pivotal trials | 50-70% | | Regulatory | Under review | 85-95% | | Approved | Marketed | 100% | ### Pipeline Progression Signals | Signal | Interpretation | |--------|----------------| | "Initiated Phase X" | Moving forward | | "Positive interim data" | Encouraging results | | "Met primary endpoint" | Success, advancing | | "Did not meet endpoint" | Failure, reassess | | "Regulatory submission" | Final stages | | "FDA priority review" | Accelerated timeline | ## Clinical Trial Analysis ### Trial Status Categories | Status | Description | Next Milestone | |--------|-------------|----------------| | Enrolling | Recruiting patients | Full enrollment | | Fully Enrolled | Recruitment complete | Data readout | | Ongoing | Treatment/observation | Primary endpoint | | Data Collection | Gathering results | Analysis | | Readout Expected | Results imminent | Announcement | ### Trial Data Timeline | Trial Phase | Typical Duration | Data Timing | |-------------|------------------|-------------| | Phase 1 | 1-2 years | End of phase | | Phase 2 | 2-3 years | Interim + final | | Phase 3 | 2-4 years | Interim + final | | Regulatory | 6-12 months | Approval decision | ## Regulatory Progress Tracking ### Submission Types | Type | Description | Timeline | |------|-------------|----------| | IND | Investigational New Drug | Pre-Phase 1 | | NDA | New Drug Application | Post-Phase 3 | | BLA | Biologics License Application | Post-Phase 3 | | sNDA | Supplemental NDA | Line extension | | EUA | Emergency Use Authorization | Expedited | ### Regulatory Milestones | Milestone | Significance | |-----------|--------------| | IND Clearance | Can begin human trials | | Fast Track | Expedited review pathway | | Breakthrough | Intensive FDA guidance | | Priority Review | 6-month review | | Standard Review | 10-12 month review | | PDUFA Date | Decision deadline | | Approval | Can commercialize | ## Portfolio Summary Analysis ### Pipeline Inventory | Stage | Count | Key Programs | |-------|-------|--------------| | Approved | 2 | COVID vaccine, RSV | | Phase 3 | 6 | CMV, Flu, Norovirus | | Phase 2 | 8 | Oncology programs | | Phase 1 | 10 | Early candidates | | Preclinical | 15+ | Discovery programs | ### Portfolio Value Framework ``` Pipeline Valuation Approach: Approved Products: - Revenue projection × multiple Phase 3 Candidates: - Peak sales potential × probability (60%) Phase 2 Candidates: - Peak sales potential × probability (30%) Phase 1 Candidates: - Option value × probability (15%) Total Pipeline Value: Sum of risk-adjusted values ``` ## Catalyst Calendar ### Building a Catalyst Tracker | Catalyst | Product | Timeline | Impact | |----------|---------|----------|--------| | Phase 3 Data | CMV Vaccine | 2025 | High | | FDA Decision | Product X | Q2 2025 | Very High | | Phase 2 Interim | Oncology | Q3 2025 | Medium | | IND Filing | New Program | Q4 2025 | Low | ### Catalyst Risk Assessment | Factor | Lower Risk | Higher Risk | |--------|------------|-------------| | Phase | Later stage | Earlier stage | | Endpoint | Objective | Subjective | | Trial Size | Large | Small | | Prior Data | Positive | Mixed | | Competition | Limited | Crowded | ## Sector-Specific Considerations ### Biotech/Pharma | Focus Area | Key Metrics | |------------|-------------| | Clinical Data | Efficacy, safety | | Regulatory Path | FDA interactions | | Commercial | Market size, pricing | | Manufacturing | Capacity, supply | ### Technology | Focus Area | Key Metrics | |------------|-------------| | Product Launches | Timing, features | | Beta Programs | User feedback | | GA Release | Availability | | Feature Roadmap | Future capabilities | ### Consumer Products | Focus Area | Key Metrics | |------------|-------------| | New SKUs | Product variants | | Distribution | Retail expansion | | Marketing | Launch support | | Consumer Testing | Reception data | ## Use Cases 1. **Pipeline Valuation**: Assess portfolio value 2. **Catalyst Trading**: Track binary events 3. **Competitive Analysis**: Compare pipelines 4. **R&D Assessment**: Evaluate innovation 5. **Investment Thesis**: Validate growth drivers 6. **Risk Analysis**: Identify pipeline gaps ## Combining with Other Skills | Skill | Combined Analysis | |-------|-------------------| | earnings-capital-allocation | R&D investment vs. pipeline | | sec-10k-analysis | Full pipeline disclosure | | earnings-competitive-review | Pipeline vs. competitors | | analyst-estimates | Pipeline in consensus | | stock-price-change | Catalyst impact on price | ## Analysis Tips 1. **Track Timelines**: Note when data is expected 2. **Compare to Prior Quarters**: What advanced or slipped? 3. **Assess Probability**: Apply success rates by stage 4. **Watch for Delays**: Slipping timelines signal issues 5. **Competitor Context**: How does pipeline compare? 6. **Commercial Potential**: Estimate peak sales for key assets ## Interpreting Results See [references/interpreting-results.md](references/interpreting-results.md) for detailed guidance on analyzing product pipeline updates.
© OctagonAI · MIT · OctagonAI/skills